Roles for RCK/DDX6 in hepatitis C virus pathogenesis and hepatocellular carcinoma
Roles for RCK/DDX6 in hepatitis C virus pathogenesis and hepatocellular carcinoma
批准号:
7698228
负责人:
PETER SARNOW
金额:
$29.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-17 至 2011-06-30
关键词:
AffectAlcohol abuseAntiviral TherapyBiochemicalBiological AssayBoxingCancer EtiologyCell physiologyCellsCessation of lifeChronicCirrhosisCytolysisCytoplasmic GranulesDegradation PathwayDetectionDiseaseEconomic BurdenFamilyFractionationGene AmplificationGene ExpressionGene Expression RegulationGenomeGoalsHepatitis BHepatitis CHepatitis C virusHepatocyteImmunoprecipitationIn Situ HybridizationIndividualInfectionInterferonsIntravenousLeadLifeLiverLiver diseasesMalignant neoplasm of liverMammalian CellMeasuresMediatingMicroRNAsMonitorNatureOligonucleotidesPathway interactionsPatientsPlasmidsPrimary carcinoma of the liver cellsProteinsRNARNA chemical synthesisRibavirinRibosomesRoleStagingStressStructureSystemTechnologyToxic Environmental SubstancesTransfectionTranslation InitiationUV inducedUp-RegulationViralViral GenomeViral ProteinsVirus Replicationcancer cellcellular targetingcholesterol biosynthesiscombatcrosslinkhelicasemembernew technologynoveloverexpressionprotein complexreconstitutionresearch studytoolviral RNAvirus pathogenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Although many cases of HCC are induced by chronic alcohol abuse or environmental toxins, approximately 80% are caused by infection with either hepatitis B or hepatitis C virus (HCV). The burden of HCV infection worldwide is very large, with most of the personal and economic burden yet to come, as cirrhosis and HCC take years to develop. Approximately 170 million people are infected worldwide with HCV. Most infected individuals do not clear the disease, but develop chronic infections that often lead to end-stage liver disease and HCC. Current treatment is limited to co-treatment with ribavirin and interferon , a therapy that is expensive and ineffective in 50% of infected individuals. Therefore, there is an urgent need to identify new and accessible viral and cellular targets for therapies against HCV and HCC. It has been shown recently that cellular microRNAs, especially those in the liver, can be readily inactivated by direct intravenous delivery of modified oligonucleotides. Thus, our finding that liver-specific microRNA miR-122 interacts directly with the viral 5’ noncoding region of HCV and that this interaction is essential to maintain intracellular abundance of the viral RNA, identifies a promising target for antiviral therapy. What are the host proteins required for microRNA expression in the liver? Recently, it has been found that host cell protein RCK/DDX6, a member of the DEAD box helicase family, is important for microRNA-mediated gene regulation in mammalian cells and that both miR-122 and RCK are greatly overexpressed in HCV-induced HCC in patient livers. Our preliminary results have shown that RCK is an essential positive regulator of HCV gene expression; depletion of RCK results in loss of HCV proteins. In this proposal, we propose to examine the mechanism by which RCK upregulates HCV gene expression at an apparently post-transcriptional step and by which RCK affects microRNA abundance and intracellular distribution in uninfected and HCV-infected liver cells. Using novel in situ hybridization technology, we will determine the effect of RCK expression on microRNA localization to specific cytoplasmic compartments known as P-bodies and stress granules. Finally, we propose experiments to identify targets for microRNAs whose abundance and distribution is affected by RCK, These studies will develop novel tools for HCV and HCC and are likely to point to new targets for antiviral therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exploring novel nucleic acid therapeutic delivery methods and therapeutic strategies
-
批准号:10514270
-
项目类别:
-
资助金额:$481.08万
-
财政年份:2022
-
负责人:PETER SARNOW
-
依托单位:
Roles for hepatitis C virus-derived circular RNAs in infected cells
-
批准号:10442607
-
项目类别:
-
资助金额:$19.68万
-
财政年份:2021
-
负责人:PETER SARNOW
-
依托单位:
Roles for hepatitis C virus-derived circular RNAs in infected cells
-
批准号:10309048
-
项目类别:
-
资助金额:$23.62万
-
财政年份:2021
-
负责人:PETER SARNOW
-
依托单位:
ANALYSIS OF VIRAL TRANSLATION COMPLEXES
-
批准号:7299499
-
项目类别:
-
资助金额:$11.6万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8417691
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification
-
批准号:9912689
-
项目类别:
-
资助金额:$54.95万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8206508
-
项目类别:
-
资助金额:$39.15万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 and circular RNAs in flavivirus RNA amplification
-
批准号:10394245
-
项目类别:
-
资助金额:$54.95万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8040024
-
项目类别:
-
资助金额:$39.09万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7763187
-
项目类别:
-
资助金额:$29.35万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8604665
-
项目类别:
-
资助金额:$39.26万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7080546
-
项目类别:
-
资助金额:$30.91万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:8789347
-
项目类别:
-
资助金额:$39.32万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7570062
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7184292
-
项目类别:
-
资助金额:$30.06万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Roles for microRNA-122 in hepatitis C virus RNA amplification
-
批准号:7340763
-
项目类别:
-
资助金额:$29.54万
-
财政年份:2006
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:6899224
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:7086229
-
项目类别:
-
资助金额:$26.87万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:6689141
-
项目类别:
-
资助金额:$27.46万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
Translational control by microRNAs
-
批准号:6758526
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2003
-
负责人:PETER SARNOW
-
依托单位:
海外基金